Myriad's HRD™ test significantly predicts response to cisplatin treatment in tr

[News]

Myriad Genetics, Inc. presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD (homologous recombination deficiency) test was significantly associated with cisplatin response in patients with triple negative breast cancer.

More... (http://www.medicalnewstoday.com/releases/270261.php)